Tag: Mydecine - Psilocybin Alpha

New: Psychedelics 2021: A Year in Review

Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans

Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans

Post published:January 24, 2022
Post category:Press Release

Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program

Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program

Post published:January 18, 2022
Post category:Press Release

Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients

Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients

Post published:January 13, 2022
Post category:Press Release

Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Post published:January 10, 2022
Post category:Press Release

Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services

Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services

Post published:January 7, 2022
Post category:Press Release

Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments

Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments

Post published:December 22, 2021
Post category:Press Release

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Post published:December 9, 2021
Post category:Press Release

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Post published:December 6, 2021
Post category:Press Release

Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021

Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021

Post published:November 10, 2021
Post category:Press Release

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients

Post published:November 3, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.